General Information


DRAVP ID  DRAVPe00684

Peptide Name   P-60

Sequence  SLIEELIKKSEEQQKKNEEELKKLEK

Sequence Length  26

UniProt ID  P03377 

Taxon ID  None

Source  Synthetic construct

Validation   Experimentally Validated



Origin Information


Gene Name/ID  Not Available

GenBank  Not Available

Amino Acid position  Not Available

Domain Accession ID  Not Available

Nucleotide sequence ID  Not Available

Molecular Type  Not Available

Chromosomal Position  Not Available



Activity Information


Target Organism  HIV

Assay  cell-fusion assay,single-cycle infection assay

Activity 

  • [Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50>750 nM);
  • HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=591.4±65.2 nM);
  • HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50>750 nM).

Hemolytic Activity  No hemolysis information or data found in the reference(s) presented in this entry

Cytotoxicity 

  • No cytotoxicity information or data found in the reference(s) presented in this entry

Binding Target  membrane

Mechanism  The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)



Structure Information


PDB ID  None

Predicted Structure Download  DRAVPe00684

Linear/Cyclic  Linear

N-terminal Modification  Acetylation

C-terminal Modification  Amidation

Other Modification  None

Stereochemistry  L



Physicochemical Information


Formula  C138H240N36O48

Absent amino acids  ACDFGHMPRTVWY

Common amino acids  E

Mass  3171.64

Pl  5.29

Basic residues  7

Acidic residues  8

Hydrophobic residues  6

Net charge  -1

Boman Index  -8833

Hydrophobicity  -166.15

Aliphatic Index  90

Half Life 

  •     Mammalian:1.9 hour
  •     Yeast:>20 hour
  •     E.coli:>10 hour

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  3



Literature Information


Literature 1

Title   Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.

Pubmed ID   30089693

Reference   J Virol. 2018 Sep 26;92(20):e01088-18.

Author   Chong H, Zhu Y, Yu D, He Y.

DOI   10.1128/JVI.01088-18